First Food and Drug Administration-Approved Prospective Trial of Primary Intracranial Stenting for Acute Stroke | Zendy

Elad I. Levy | Zendy; Adnan H. Siddiqui | Zendy; Annemarie Crumlish | Zendy; Kenneth V. Snyder | Zendy; Erik F. Hauck | Zendy; David Fiorella | Zendy; L. Nelson Hopkins | Zendy; J Mocco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First Food and Drug Administration-Approved Prospective Trial of Primary Intracranial Stenting for Acute Stroke

Author(s) -

Elad I. Levy,

Adnan H. Siddiqui,

Annemarie Crumlish,

Kenneth V. Snyder,

Erik F. Hauck,

David Fiorella,

L. Nelson Hopkins,

J Mocco

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.561274

Subject(s) - medicine , food and drug administration , stroke (engine) , acute stroke , drug , clinical trial , surgery , intensive care medicine , pharmacology , mechanical engineering , tissue plasminogen activator , engineering

Acute revascularization is associated with improved outcomes in ischemic stroke patients. However, it is unclear which method of intraarterial intervention, if any, is ideal. Numerous case series and cardiac literature parallels suggest that acute stenting may yield high revascularization levels with low associated morbidity. We therefore conducted a Food and Drug Administration-approved prospective pilot trial to evaluate the safety of intracranial stenting for acute ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research